A narrow-band ultraviolet B course improves vitamin D balance and alters cutaneous CYP27A1 and CYP27B1 mRNA expression levels in haemodialysis patients supplemented with oral vitamin D

      Research output: Research - peer-reviewArticle

      • Meri J Ala-Houhala
      • Katja Vähävihu
      • Erna Snellman
      • Taina Hasan
      • Hannu Kautiainen
      • Piia Karisola
      • Yvonne Dombrowski
      • Jürgen Schauber
      • Heikki Saha
      • Timo Reunala

      View graph of relations

      Background: Chronic kidney disease (CKD) patients on dialysis are prone to vitamin D insufficiency despite oral vitamin D supplementation. Here, we studied whether narrow-band ultraviolet B (NB-UVB) exposures improve vitamin D balance.

      Methods: 14 haemodialysis patients and 15 healthy subjects receiving oral cholecalciferol 20 µg daily got nine NB-UVB exposures on the entire body. Serum 25-hydroxyvitamin D (25(OH)D) was measured by radioimmunoassay. Cutaneous mRNA expression levels of CYP27A1 and CYP27B1, two enzymes required for hydroxylation of vitamin D into its active metabolite, were also measured.

      Results: The baseline serum 25(OH)D concentration was 57.6 ± 18.2 nmol/l in the CKD patients and 74.3 ± 14.8 nmol/l in the healthy subjects. The NB-UVB course increased serum 25(OH)D by 14.0 nmol/l (95% CI 8.7-19.5) and 17.0 nmol/l (CI 13.7-20.2), respectively. At baseline the CKD patients showed significantly increased CYP27B1 levels compared to the healthy subjects.

      Conclusions: A short NB-UVB course is an efficient way to improve vitamin D balance in CKD patients on dialysis who are receiving oral vitamin D supplementation. The increased cutaneous CYP27B1 levels in the CKD patients suggest that the loss of renal activity of this enzyme is at least partially compensated for by the skin.


      Original languageEnglish
      Number of pages6
      Pages (from-to)17-22
      JournalNephron Clinical Practice
      Journal publication dateDec 2013
      Issue number1-2
      StatePublished - Dec 2013

        Research areas

      • 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, Administration, Oral, Adolescent, Aged, Cholestanetriol 26-Monooxygenase, Combined Modality Therapy, Dietary Supplements, Female, Humans, Male, RNA, Messenger, Renal Dialysis, Renal Insufficiency, Chronic, Skin, Steroid Hydroxylases, Treatment Outcome, Ultraviolet Therapy, Vitamin D, Vitamin D Deficiency, Young Adult

      ID: 11708505